Chih Ming Chen
Chief Executive Officer at TWI PHARMACEUTICALS INC
Chih Ming Chen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| TWI PHARMACEUTICALS INC | Chief Executive Officer | 01/12/1997 | - |
| Chairman | 05/01/2004 | - | |
| Founder | 01/12/1997 | - | |
| Public Communications Contact | 01/12/1997 | - | |
| President | 01/12/1997 | - | |
TWi Pharmaceuticals Holding, Inc.
 TWi Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services. | Director/Board Member | - | - |
| Delightful Cheers Ltd. | Director/Board Member | - | - |
| Eldridge Capital Group Ltd. | Director/Board Member | - | - |
Allgenesis Biotherapeutics, Inc.
 Allgenesis Biotherapeutics, Inc. BiotechnologyHealth Technology Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014. | Chairman | - | - |
| Founder | - | - |
Career history of Chih Ming Chen
Former positions of Chih Ming Chen
| Companies | Position | Start | End |
|---|---|---|---|
Jiachen International Pharmaceutical Co., Ltd.
 Jiachen International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Jiachen International Pharmaceutical Co., Ltd. engages in the investment, biotechnology service and management consulting industries. The company was founded on February 15, 2019 and is headquartered in Taipei, Taiwan. | Chairman | - | - |
| TWI BIOTECHNOLOGY, INC. | Chairman | - | - |
| Founder | 16/07/2010 | - |
Training of Chih Ming Chen
| The Ohio State University | Doctorate Degree |
| National Taiwan University | Undergraduate Degree |
Statistics
International
| Taiwan | 7 |
| United States | 3 |
| Cayman Islands | 2 |
Operational
| Chairman | 4 |
| Founder | 3 |
| Director/Board Member | 3 |
Sectoral
| Health Technology | 6 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| TWI BIOTECHNOLOGY, INC. | Health Technology |
| Private companies | 6 |
|---|---|
TWi Pharmaceuticals, Inc.
 TWi Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals, Inc. operates as a technology-based special pharmaceutical company. The firm engages in the development and commercialization of high barrier generics drugs. Its products include donepezil hydrochloride tablets, megestrol acetate oral suspension, hydroquinone cream, guanfacine extended-release tablets and nifedipine extended-release tablets. The company was founded by Chih Ming Chen on December 1, 1997 and is headquartered in Taipei, Taiwan. | Health Technology |
TWi Pharmaceuticals Holding, Inc.
TWi Pharmaceuticals Holding, Inc. Pharmaceuticals: MajorHealth Technology TWi Pharmaceuticals Holding, Inc. provides pharmaceutical services. | Health Technology |
| Delightful Cheers Ltd. | |
| Eldridge Capital Group Ltd. | |
Jiachen International Pharmaceutical Co., Ltd.
Jiachen International Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Jiachen International Pharmaceutical Co., Ltd. engages in the investment, biotechnology service and management consulting industries. The company was founded on February 15, 2019 and is headquartered in Taipei, Taiwan. | Health Technology |
Allgenesis Biotherapeutics, Inc.
Allgenesis Biotherapeutics, Inc. BiotechnologyHealth Technology Allgenesis Biotherapeutics, Inc. is a Taiwanese clinical-stage biopharmaceutical company focused on researching and developing novel medicines for the treatment of eye diseases. The private company is based in Taipei, Taiwan. The company's current pipeline includes potential blockbuster drugs such as ag-73305 for the treatment of DME, NAMD, and other retinal diseases, as well as ag-80308 for dry eye disease. The company was founded by Chih Lung Shen and Chih Ming Chen. Madhu Cherukury has been the CEO of the company since 2014. | Health Technology |
- Stock Market
- Insiders
- Chih Ming Chen
- Experience
